Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susanne Stowasser

Showing results (11-20 of 61) with videos related to

Pageof 7
Sort By:
Respiratory Research|September 5, 2018
Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSIS® trialsUlrich Costabel, Jürgen Behr, Bruno Crestani, et al.
ERJ Open Research|May 3, 2019
Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stageChristopher J Ryerson, Martin Kolb, Luca Richeldi, et al.
The European Respiratory Journal|March 7, 2015
Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosisLutz Wollin, Eva Wex, Alexander Pautsch, et al.
BMC Pulmonary Medicine|January 10, 2020
Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosisLuca Richeldi, Martin Kolb, Stéphane Jouneau, et al.
Respirology (Carlton, Vic.)|July 23, 2019
Long-term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: Results from INPULSIS®-ONJin Woo Song, Takashi Ogura, Yoshikazu Inoue, et al.
Advances in Therapy|May 16, 2022
Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung DiseasesFrancesco Bonella, Vincent Cottin, Claudia Valenzuela, et al.
American Journal of Respiratory and Critical Care Medicine|August 1, 2019
Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction. A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE)Jürgen Behr, Martin Kolb, Jin Woo Song, et al.
Respiratory Research|October 31, 2013
Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trialKai M Beeh, Thomas Glaab, Susanne Stowasser, et al.
Advances in Therapy|February 8, 2019
Subgroup Analysis for Chinese Patients Included in the INPULSIS<sup>®</sup> Trials on Nintedanib in Idiopathic Pulmonary FibrosisZuojun Xu, Huiping Li, Fuqiang Wen, et al.
BMJ Open Respiratory Research|June 11, 2019
Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trialsLisa Lancaster, Bruno Crestani, Paul Hernandez, et al.
Pageof 7

Showing results (11-20 of 61) with videos related to

Sort By:
Pageof 7
Respiratory Research|September 5, 2018
Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSIS® trialsUlrich Costabel, Jürgen Behr, Bruno Crestani, et al.
ERJ Open Research|May 3, 2019
Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stageChristopher J Ryerson, Martin Kolb, Luca Richeldi, et al.
The European Respiratory Journal|March 7, 2015
Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosisLutz Wollin, Eva Wex, Alexander Pautsch, et al.
BMC Pulmonary Medicine|January 10, 2020
Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosisLuca Richeldi, Martin Kolb, Stéphane Jouneau, et al.
Respirology (Carlton, Vic.)|July 23, 2019
Long-term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: Results from INPULSIS®-ONJin Woo Song, Takashi Ogura, Yoshikazu Inoue, et al.
Advances in Therapy|May 16, 2022
Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung DiseasesFrancesco Bonella, Vincent Cottin, Claudia Valenzuela, et al.
American Journal of Respiratory and Critical Care Medicine|August 1, 2019
Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction. A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE)Jürgen Behr, Martin Kolb, Jin Woo Song, et al.
Respiratory Research|October 31, 2013
Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trialKai M Beeh, Thomas Glaab, Susanne Stowasser, et al.
Advances in Therapy|February 8, 2019
Subgroup Analysis for Chinese Patients Included in the INPULSIS<sup>®</sup> Trials on Nintedanib in Idiopathic Pulmonary FibrosisZuojun Xu, Huiping Li, Fuqiang Wen, et al.
BMJ Open Respiratory Research|June 11, 2019
Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trialsLisa Lancaster, Bruno Crestani, Paul Hernandez, et al.
Pageof 7